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T cell acute lymphoblastic leukemias (ALLs 
[T-ALLs]) are aggressive malignancies derived 
from the transformation of lymphoblastic pre-
cursors in the thymus. Despite major therapeu-
tic improvements, a fraction of patients with 
T-ALL still relapse and experience eventual re-
fractory leukemia (Bailey et al., 2008; Pui et al., 
2008). T-ALLs are characterized by the deregu-
lated expression of oncogenic transcription 
factors combined with the frequent inactiva-
tion of the tumor suppressor CDKN2A/P16/
ARF and activation of the NOTCH1 path-
way (Ferrando et al., 2002; Weng et al., 2004;   
De Keersmaecker et al., 2005; Soulier et al., 2005; 
Aifantis et al., 2008). Recently, high-resolution 
cytogenetic tools have identified frequent addi-
tional cryptic deletions and duplications in T-ALL 
cells (Clappier et al., 2007; Van Vlierberghe et al., 
2008; Gutierrez et al., 2009; Tosello et al., 2009; 
Kleppe et al., 2010). We used our established 
xenotransplantation assay of human T-ALL in 
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Genomic studies in human acute lymphoblastic leukemia (ALL) have revealed clonal hetero-
geneity at diagnosis and clonal evolution at relapse. In this study, we used genome-wide 
profiling to compare human T cell ALL samples at the time of diagnosis and after engraft-
ment (xenograft) into immunodeficient recipient mice. Compared with paired diagnosis 
samples, the xenograft leukemia often contained additional genomic lesions in established 
human oncogenes and/or tumor suppressor genes. Mimicking such genomic lesions by short 
hairpin RNA–mediated knockdown in diagnosis samples conferred a selective advantage in 
competitive engraftment experiments, demonstrating that additional lesions can be drivers 
of increased leukemia-initiating activity. In addition, the xenograft leukemias appeared to 
arise from minor subclones existing in the patient at diagnosis. Comparison of paired 
diagnosis and relapse samples showed that, with regard to genetic lesions, xenograft leuke-
mias more frequently more closely resembled relapse samples than bulk diagnosis samples. 
Moreover, a cell cycle– and mitosis-associated gene expression signature was present in 
xenograft and relapse samples, and xenograft leukemia exhibited diminished sensitivity to 
drugs. Thus, the establishment of human leukemia in immunodeficient mice selects and 
expands a more aggressive malignancy, recapitulating the process of relapse in patients. 
These findings may contribute to the design of novel strategies to prevent or treat relapse.
© 2011 Clappier et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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a series of T-ALL patients who had further relapsed; mice 
were injected with the patient diagnosis sample, and the 
resulting xenograft, diagnosis, and relapse DNA triads were 
compared (n = 8 triads). In all triads but one, relapse and xeno-
graft samples harbored a range of new genomic lesions compared 
with diagnosis cells (Figs. 1 G and 2 and Tables S1 and S3).   
Oncogenetic trees showed that the xenograft and the relapse 
leukemia cells had derived not from the bulk diagnosis cells 
but from a common prediagnosis ancestor cell in seven of eight 
T-ALL triads, as did the diagnosis cells, which is consistent 
with a branched rather than linear clonal evolution (Fig. 2).   
In five out of eight cases (XLE_61, XLE_92, XLE_95, XLE_96, 
and XLE_98), the xenograft and relapse clones were located 
in the same branch, whereas in two cases, the xenograft clone 
was closer to the bulk diagnosis clone (XLE_93 and XLE_97), 
and in one case the three clones were equally distinct (XLE_94). 
It is noteworthy that distinct genetic lesions targeting the 
same gene could be found in several samples from the same 
patient (like CDKN2A/P16/ARF deletions, MYB duplica-
tions, and NOTCH1 mutations), demonstrating that they 
had independently arisen more than once (Fig. 2). Altogether, 
these results are consistent with a neo-Darwinian genetic 
diversification of leukemia, in accordance with the model of 
Anderson et al. (2011), that is especially uncovered by relapse 
or xenograft.
Additional genomic lesions of xenograft leukemias  
can be drivers of increased leukemia-initiating activity
At this point, we reasoned that if some additional genomic 
abnormalities observed in the engrafted subclones were respon-
sible for their preferential engraftment, this advantage should 
be  conserved  when  primary  xenograft  cells  are  reinjected 
into secondary recipients. Indeed, xenografted cells reestab-
lished leukemia more rapidly than diagnosis cells in secondary 
versus primary xenografts experiments (Fig. S3). Although in-
creased proliferation could be involved in such accelerated 
secondary engraftment, clonal selection may also have enriched 
the xenograft leukemia in leukemic stem cells, as suggested by 
limiting-dilution analyses (Fig. S3 C). Interestingly, Boiko et al. 
(2010) have suggested that the more cancers are advanced, the 
more efficiently they engraft, which is consistent with a pro-
gressive enrichment in cancer stem cells and the loss of hier-
archical structure as tumors progress.
We then sought to model the selective advantage and gain 
of malignancy likely conferred by the acquisition of an addi-
tional genomic lesion in leukemia cells. The tumor suppressor 
gene PTEN was a good candidate here as (i) it is involved in 
both proliferation and leukemia stem cell properties (Yilmaz 
et al., 2006), (ii) it has been associated with cancer progression 
and relapse including in T-ALL (Palomero et al., 2007; Gutierrez 
et al., 2009), and (iii) we found it newly mutated or deleted in 
xenograft leukemia cells from several patients (Fig. 1 F and 
Tables S2 and S3). Using lentiviral transduction, we genetically 
modified the diagnosis primary leukemia cells (Gerby et al., 
2010) of a patient who had further relapsed and harbored a 
PTEN deletion in both his relapse and xenografted cells but 
immunodeficient mice (nonobese diabetic [NOD]/scid or 
NOD/scid/IL-2R null; Armstrong et al., 2009) to test the 
hypothesis that xenografted leukemia cells could experience 
clonal evolution.
RESULTS AND DISCUSSION
Establishment of xenograft leukemias frequently selects 
minor genetic subclones, reminiscent of relapse in patients
We compared by high-density DNA arrays the genome of a 
series of 18 primary  T-ALL cases at the time of diagnosis (diag-
nosis leukemia) and after primary engraftment in immuno-
deficient mice (xenograft leukemia; Fig. 1 A). A very good 
overall stability of the T-ALL genome was observed in all 
cases, with a pattern of copy number alterations being largely 
consistent between diagnosis and xenograft leukemia samples 
(Fig. S1 and Table S2). However, some changes were also ob-
served (Fig. 1 and Table S2). Strikingly, these new genomic 
abnormalities in xenograft cells mainly targeted genes known 
as human oncogenes or tumor suppressor genes like PTEN, 
MYC, MYB, CDKN2A, DLEU7, or WT1. Sequencing T-ALL 
cancer genes NOTCH1, FBXW7, and PTEN also showed 
changes in the mutation pattern of xenograft versus diagnosis 
cells (Fig. 1 D and Table S3). Altogether, genomic changes 
were detected in 12 out of 18 T-ALL pairs (67%). In some 
cases, the stepwise sequence of genomic events could be re-
constructed and demonstrated that xenograft cells had derived 
not from the diagnosis cells but from a common prediagnosis 
ancestor cell (Fig. S2, A and B). To investigate whether the ad-
ditional genomic abnormalities found in xenograft leukemia 
cells occurred de novo in the mouse or had preexisted in the 
patient, we performed highly sensitive lesion-specific genomic 
PCR backtracking to test for their presence in rare cells at   
diagnosis. In the four analyzed cases, the genomic lesions were 
indeed detected at low levels in the diagnosis sample, demon-
strating that the engrafted leukemia in the mouse had arisen 
from a minor genetic subclone present in the patient’s leuke-
mia (Fig. 1 F and Fig. S2 C). These results, along with the fact 
that the additional lesions target cancer genes, suggest that 
clonal selection related to the activation of prototypical human 
oncogenic pathways occurs during leukemia reinitiation and 
expansion in immunodeficient mice.
Intraclonal heterogeneity at diagnosis and clonal evolu-
tion at relapse have been reported in human ALL (Zuna et al., 
2004; Choi et al., 2007; Mullighan et al., 2008; Yang et al., 2008; 
Tosello et al., 2009; Anderson et al., 2011). Genomic analysis 
of relapsing ALLs has suggested that the relapse frequently 
does not simply result from mutations of specific drug-resistance 
genes but rather from additional oncogenic abnormalities that 
contribute to the emergence of a leukemic subclone (Mullighan 
et al., 2008). Reminiscent of this process, our results suggest 
that development of human leukemia in the immunodeficient 
mouse does not simply result from specific adaptation to the 
mouse environment but rather from the oncogenic selection 
and expansion of a preexisting leukemic subclone. Therefore, 
we hypothesized that leukemia reinitiation in the mouse could 
mirror the leukemia relapse process in patients. We investigated   JEM VOL. 208, April 11, 2011  655
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Figure 1.  Genomic changes associated with clonal selection in xenografted leukemias. (A) Strategy of sample analysis. (B) Array CGH plots show-
ing focal deletions in a T-ALL case, either in xenografted cells only (WT1 locus at 11p13) or present in both diagnosis and xenografted cells (11q14.2 locus). 
(C) FISH analysis of TCR- (red probe) and MYC (green probe) loci in diagnosis and xenografted leukemia cells. Bar, 12 µm. (D) DNA sequence chromato-
grams showing NOTCH1 and PTEN mutations in xenograft samples. Arrows indicate the mutated nucleotides. (E) List of cancer-associated genes targeted 
by genomic changes in xenograft leukemias. (F) Representative lesion-specific genomic PCR backtracking in a T-ALL case: focal PTEN deletion as detected 
by array CGH in the xenograft but not the diagnosis bulk leukemia cells, sequence of the deletion breakpoints junction, and amplification curves from 
specific quantitative PCR experiments of the undiluted diagnosis sample (indicated by an arrow) compared with 10-fold dilutions of the xenograft sample 
from 10% to 0.01%. The horizontal green line indicates the threshold for PCR linearity. The horizontal purple line is the cursor of the Genomic Workbench 
software, centralized on the deletion. Each quantitative PCR point was performed in duplicate. (G) Array CGH plots in a T-ALL triad case showing an 11q 
deletion in both the xenograft and relapse but not in the diagnosis samples. XLE, unique identification numbers for T-ALL cases.656 Clonal selection in human T-ALL | Clappier et al.
mitosis (see Gene Ontology annota-
tions in Table S1), suggesting that an 
increased proliferation contributes to 
the  selective  advantage  of  the  en-
grafted cells. The xenograft signature 
also  included  a  few  other  unrelated 
genes, including CD133 (PROMD1/ 
Prominin-1), which is a marker of he-
matopoietic stem cells and of cancer 
stem cells (Singh et al., 2004). Interest-
ingly, the xenograft signature was strongly expressed in all of 
the nine xenograft samples relative to the paired diagnosis 
samples, including in three cases without identified additional 
genomic changes in the xenograft sample (cases XLE_40, 
XLE_52, and XLE_69; Fig. 4 B). Cryptic genomic lesions or 
epigenetic mechanisms could be involved in these cases, also 
converging on cell cycle and proliferation.
Several studies have found cell cycle, mitosis, and prolifer-
ation signatures in relapsing ALL patients (Bhojwani et al., 
2006; Kirschner-Schwabe et al., 2006; Staal et al., 2010). We 
analyzed the relevance of the xenograft signature in relapse 
samples from patients. We performed gene set enrichment 
analyses using the expression data from two independent 
series of paired diagnosis and relapse ALLs (Bhojwani et al., 
2006; Staal et al., 2010). Strikingly, the xenograft signature was 
significantly enriched in the relapse cells relative to the diag-
nosis cells in both series (Fig. 4 C). These data indicate that 
xenograft and relapse leukemias share a unique profile of in-
creased proliferation and highlight the relevance of the xeno-
graft leukemia system to model patient relapse.
Although the majority of ALL patients at diagnosis re-
spond well to treatment and reach complete remission, pa-
tients who relapse frequently experience drug resistance and 
eventual refractory leukemia (Klumper et al., 1995; Choi et al., 
2007; Bailey et al., 2008). Additional oncogenic abnormalities, 
like PTEN inactivation, could be involved in acquired resis-
tance to treatment (Palomero et al., 2007). Because we found 
evidence of clonal selection and gain of malignancy in xeno-
grafted leukemia cells, we assessed whether this oncogenic 
progression was also associated with an acquired diminished 
not in the bulk diagnosis cells. Competitive engraftment ex-
periments clearly demonstrated the selective advantage of PTEN 
knockdown leukemia cells over control diagnosis leukemia 
cells (Fig. 3, A–C). Moreover, kinetics and limiting-dilution 
analyses in noncompetitive engraftment experiments showed 
an increased leukemia initiating activity caused by PTEN 
knockdown in primary leukemia cells (Fig. 3 D). These results 
demonstrate that the additional genomic lesions in xenograft 
leukemia can be drivers of the increased malignancy and re-
lated clonal selection of the human leukemia cells in mice. 
Importantly, this original experimental strategy faithfully re-
produces the process of tumor progression from diagnosis to-
ward relapse.
Xenograft samples strongly express cell cycle and mitosis 
genes and display in vitro diminished sensitivity to drugs, 
reminiscent of leukemias at relapse
To gain insight into the functional changes of the xenograft 
cells relative to diagnosis cells, we profiled by large-scale ex-
pression analysis 9 paired xenograft and diagnosis T-ALL samples 
along with 93 other human T-ALL samples. First, unsuper-
vised analysis showed that the diagnosis and xenograft samples 
from the same patient clustered next to one another for all 
pairs,  demonstrating  the  excellent  overall  relevance  of  the   
xenograft model (Fig. 4 A). We then performed a paired super-
vised analysis that sorted out a list of up-regulated genes that 
individually differentiated the xenografts from the correspond-
ing diagnosis leukemias (Fig. 4 B; the list of genes is in the 
supplemental material). Strikingly, this list was dramatically 
enriched in a cluster of genes clearly linked to cell cycle and 
Figure 2.  Oncogenetic trees for the  
diagnosis, xenograft, and relapse T-ALL  
triads. The stepwise sequence of genomic 
events could be reconstructed from the DNA 
copy number and sequence data in the sam-
ples. XLE, unique identification numbers for 
the T-ALL cases; D, diagnosis; X, xenograft; R, 
relapse samples; R*, in the case of the triad 
XLE_61, limited genomic DNA at relapse al-
lowed only to backtrack the PTEN lesions seen 
in the xenograft. Superscript letters indicate 
genomic alterations that involve different 
breakpoints or sequence mutation of the 
same locus or gene in the diagnosis, xeno-
graft, and/or relapse samples from the same 
T-ALL case.JEM VOL. 208, April 11, 2011  657
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of xenograft samples to treatment, as observed in patients at 
relapse. This is strengthened by our finding that xenograft 
cells, like relapsing cells, often have additional genomic lesions 
targeting cancer genes that are related to cell cycle and prolif-
eration rather than specific drug-resistance genes. Such mech-
anisms could contribute to the poor response to treatment of 
relapsing leukemia. It is noteworthy that additional mutations 
in PTEN, MYC, or NOTCH1, as found in this study in xeno-
graft leukemias, may also modulate the NOTCH pathway 
and thus the sensitivity of the leukemia cells to -secretase 
inhibitors (Weng et al., 2004; Palomero et al., 2006, 2007).
Despite major therapeutic improvement in ALL, relapsing 
patients still have a dismal prognosis, highlighting the need 
for more efficient strategies to treat these aggressive tumors. 
Our data indicate that the development of human T-ALL in 
sensitivity to drugs. We therefore assayed the sensitivity of 
xenografted leukemia samples to glucocorticoids, which are 
essential components of ALL treatment, and to -secretase 
inhibitors, which synergistically target T-ALL cells as the re-
sult of oncogenic activation of the NOTCH1 pathway (Weng 
et al., 2004; Real et al., 2009). In vitro cultures of leukemia 
samples on the Notch ligand–expressing stromal cells MS5-
DL1 (Armstrong et al., 2009) first confirmed that xenografted 
cells were much more proliferative than diagnosis cells (Fig. 4 D). 
Moreover, although xenograft cells were still inhibited in a 
dose-dependent manner, high doses of glucocorticoids were 
necessary to efficiently reduce the cell number, and the addi-
tion of -secretase inhibitors was required to increase apop-
tosis (Fig. 4 D). These data suggest that increased proliferation 
and inhibition of apoptosis result in an overall lesser sensitivity 
Figure 3.  PTEN knockdown confers a selective advantage to diagnosis leukemia cells. (A) Schematic of the protocol for competitive engraftment 
experiments shown in B and C. Case XLE_61 T-ALL diagnosis cells transduced with control shRNA (shRNA CTL and CTL-Cherry+ cells) and shRNA PTEN 
(PTENKD-GFP+ cells) lentivectors were sorted and co-transplanted in equal number into NSG mice. Two cell doses (5 × 104 and 5 × 103 cells per mouse) 
were tested; three to five mice were injected per cell dose. Immunoblots show PTEN silencing efficiency. (B) Flow cytometry analyses showing the propor-
tion of PTENKD-GFP+ and CTL-Cherry+ cells in leukemia cells immediately before transplantation (left) and in BM cells of a representative mouse after  
establishment of leukemia (right). (C) PTENKD-GFP+ versus CTL-Cherry+ CD45+ cells ratios are indicated, and each dot represents data of one mouse.  
The dotted line indicates ratio 1. (D) Kinetics of engraftment of cells transduced with shRNA CTL (CTL-GFP+ cells) and shRNA PTEN (PTENKD-GFP+ cells) 
lentivectors, injected in parallel (noncompetitive) experiments with decreasing cell doses, as measured by the percentage of CD45+GFP+ cells in BM cells. 
Each dot represents data of one mouse, dashes represent medians, and lines connect the medians.658 Clonal selection in human T-ALL | Clappier et al.
Figure 4.  Increased proliferation and overall diminished drug sensitivity in xenografted leukemias. (A) Paired diagnosis and xenograft leuke-
mias were analyzed by unsupervised large-scale gene expression profiling. 9 pairs of diagnosis and xenograft T-ALL samples along with a series of 73 JEM VOL. 208, April 11, 2011  659
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Mice. Immunodeficient NOD.CB17-Prkdc(scid) (abbreviated NOD/scid 
[NS])  and  NOD.Cg-Prkdc(scid)Il2rg(tm1Wjll)/SzJ  (abbreviated  NOD/
scid/IL-2R null [NSG]) were both obtained from the Jackson Laboratory. 
Mice were housed in pathogen-free animal facilities at the Institut de Radio-
biologie Cellulaire et Moléculaire (Commissariat à l’Energie Atomique,   
Fontenay-aux-Roses, France). All experimental procedures were performed 
in compliance with the French Ministry of Agriculture regulations (ani-
mal facility registration number A920322) for animal experimentation.
Xenotransplantation. Mice (6–8 wk old) were sublethally irradiated at   
3 Gy (IBL 637 CisBio International; dose rate 0.61 Gy/min) and anesthetized 
with isoflurane before injection. Human leukemia cells were transplanted 
into the retro-orbital sinus. Development of human T-ALL in mice was fol-
lowed up using intrafemoral BM sampling. Conjugated mouse anti–human-
specific  monoclonal  antibodies  PE-CD45  and  PE.Cy7-CD7  (Beckman 
Coulter) and FACS analysis (FACSCalibur; BD) were used to identify human 
leukemia cells. Mice were euthanized when they reached endpoints set to 
meet accepted animal care guidelines. For the initial series of xenotransplan-
tation, 5 × 104 to 5 × 106 leukemia cells were transplanted into either NS or 
NSG mice; for all further experiments, NSG mice were used.
Sample preparation and DNA and RNA extraction. White blood cells 
from patient samples were isolated by Ficoll centrifugation and cryopreserved 
using standard procedures. After thawing, cells were spun down, and DNA 
was extracted with the DNA blood mini kit (QIAGEN). RNA extraction 
for large-scale analysis was performed with the miRNeasy (QIAGEN). 
Nucleic acid quantity and quality was assessed using a spectrophotometer 
(ND-1000; NanoDrop).
Genome-wide DNA array analysis. Genomic DNAs from paired diag-
nosis and xenograft samples (n = 25 patients) and from corresponding relapse 
leukemia samples (in 7 of these patients) were analyzed by high-density array 
comparative genomic hybridization (CGH) technologies using the 1 × 1M 
Microarray SurePrint G3 Catalog (Agilent Technologies) or by single nucleotide 
polymorphism (SNP) array technologies using the Genome-Wide Human 
SNP Array 6.0 (Affymetrix) according to the manufacturers’ recommenda-
tions (total n = 42 and n = 14 DNA samples, respectively; each sample origi-
nating from the same patient was analyzed by the same technology). All 
Microarray SNP/CGH array data files are available from ArrayExpress under 
accession no. E-MTAB-593. Analyses were performed using the Genomic 
Workbench software (Agilent Technologies) with the help of the ADM-2 
algorithm for array CGH data, Genomic Suite 6.5 software (Partek), and the 
Hidden Markov Model and Segmentation algorithms for SNP-based copy 
number and genotyping analyses. The final retained abnormalities were vali-
dated by two investigators (E. Clappier and J. Soulier) by visual analysis con-
sidering the size and Log2 ratios of the abnormalities with respect to the 
individual background noise of each array at each particular chromosomal 
location, as reported previously (Clappier et al., 2007; Kleppe et al., 2010). 
Final validated data are provided in Tables S2 and S3. The University of Cali-
fornia, Santa Cruz Genome Browser was used for locating genes on the human 
genome. Polymorphic copy number variations were excluded using the 
Database of the Genomic Variants tracks in the University of California, 
Santa Cruz Genome Browser or in the Genomic Workbench software.
immunodeficient mice favors the emergence of leukemic 
subclones with enhanced leukemia-initiating activity, increased 
proliferation, and diminished overall sensitivity to drugs and 
therefore recapitulates key biological features of the postther-
apeutic tumor progression process in patients (Fig. S4). Im-
portantly, the additional genetic lesions found in xenografted 
cells target human cancer–associated genes like in relapsing 
cells and they can be drivers of tumor progression. Future anti-
leukemic strategies will have to consider the subclonal origin 
of leukemia relapse. In particular, it would be critical to iden-
tify and eradicate minor leukemia subclones during the initial 
phase of treatment (Bailey et al., 2008; Freyer et al., 2011). The 
biological mechanisms underlying relapse will have to be ex-
tensively analyzed at the genomic (including whole genome 
sequencing),  epigenetic,  and  functional  levels.  Interestingly, 
our gene expression profiling analysis suggests that despite the 
complexity of the genomic lesions, the pathways of tumor 
progression in xenograft and in patients at relapse share unique 
features. The xenograft leukemia model is thus relevant and 
should be helpful to design new strategies to prevent or treat 
relapse in patients (Fig. S4).
Cancer cells are functionally heterogeneous, and in several 
cancers, a cellular hierarchy has been described with cancer stem 
cells at the apex (Dick, 2008). Xenotransplantation in immu-
nodeficient mice is currently the key assay to evaluate human 
cancer stem cells activity. By demonstrating that genetic sub-
clones are frequently selected in xenograft of T-ALL cells 
and that genetic lesions in these subclones can modulate 
leukemia-initiating activity and drive a gain of malignancy, 
our results add a new level of complexity that should be con-
sidered when characterizing human ALL leukemic stem cells 
(Dick, 2008; Shackleton et al., 2009; Anderson et al., 2011).
MATERIALS AND METHODS
T-ALL patients. T-ALL samples were obtained from patients who were 
treated at Hôpital Saint-Louis or Hôpital Trousseau (Paris, France) according 
to the national protocols. Informed consent was obtained from the patients 
or their relatives. The Institutional Review Board of the Institut Universitaire 
d’Hématologie, Université Paris Diderot approved the study. BM or periph-
eral blood samples from 18 T-ALL patients were used for the first set of 
xenograft experiments. For a second set of experiments, seven more cases 
with available cryopreserved paired samples both at diagnosis and at relapse 
were studied. There were 22 children and 3 adults. For the large-scale gene ex-
pression analysis, 9 pairs of T-ALL diagnosis and xenograft samples were exam-
ined in addition to 73 cryopreserved T-ALL samples of patients from Hôpital 
Saint-Louis, 20 human T-ALL cell lines, and 1 normal BM sample. Only 
samples with at least 80% leukemia cells were used. The T-ALL cell lines were 
obtained from DSMZ.
primary T-ALL cases and 20 T cell lines were analyzed; the 9 pairs are boxed vertically in black. TAL_R, TLX/HOX_R, and immature T-ALL refer to the 
classification of T-ALL subtypes based on gene expression and genomic annotations as reported for another T-ALL series (Soulier et al., 2005). The cell 
cycle and mitosis cluster is boxed horizontally in black. (B) Gene clustering of the 59 unique genes of the xenograft signature, as defined by reference 
to the paired primary samples (“overexpressed in T-ALL xenografts gene set”). Representative genes are shown on the right of the heat map. (C) Gene 
set enrichment analysis (GSEA) of the xenograft gene set in the relapse versus diagnosis samples of two independent ALL series (Bhojwani et al., 2006; 
Staal et al., 2010). (D) Proliferation, apoptosis, and dose-dependent inhibition of paired diagnosis and xenograft leukemia samples treated with dexa-
methasone (dexa), -secretase inhibitor (GSI), or both, compared with vehicle only (DMSO; -). Proliferation was assessed as the number of KI67+ cells, 
apoptosis as the percentage of annexin V+ cells, and dose-dependent inhibition as the cell number fold change (treated/vehicle). Error bars represent 
means ± SD of triplicate experiments.
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PTEN gene silencing in primary T-ALL cells. The pSuper construct 
containing PTEN short hairpin RNA (shRNA) was generated by cloning 
the following human PTEN-specific RNA interference target sequence into 
the pSuper plasmid: 5-AGACAAAGCCAACCGATAC-3. The H1-shRN-
APTEN fragment was then subcloned into the pTRIP/U3-MND-GFP 
where the green fluorescent protein coding sequence is under the control of 
the MND promoter as previously done for a control shCTL directed against 
the human hepatitis B virus. A lentiviral vector encoding the red fluorescent 
protein Cherry was subsequently derived from this plasmid. Human T-ALL 
samples were transduced with unconcentrated G/IL-7SUx envelope pseudo-
typed vectors as previously reported (Gerby et al., 2010). In brief, human T-ALL 
cells were co-cultured during 48 h with the mouse stromal cells expressing 
the Notch ligand DL1 MS5-DL1 in reconstituted -MEM supplemented 
with 10% FCS and 10% human AB serum, in the presence of stem cell factor, 
rhFlt3-L, insulin, and rhIL-7 as reported previously (Gerby et al., 2010). Leu-
kemia cells were then spinoculated for 2 h in the presence of plastic-bound 
human DL1, 2.5 µg/ml protamine sulfate, and G/IL-7SUx pseudotyped len-
tiviral vectors, and transduction was continued for a further 48 h. Cells were 
again co-cultured with MS5-DL1 cells plus cytokines during 1 wk for maximal 
reporter fluorescent protein expression. Transduced leukemia cells were then 
sorted (Flow cytometer Influx; BD) based on the CD45+CD7+ and GFP+ or 
Cherry+ phenotype before transplantation into immunodeficient mice.
In vitro drug sensitivity assay. Diagnosis and xenograft leukemia cells 
were co-cultured for 1 wk with MS5-DL1 cells, as described previously 
(Gerby et al., 2010), in the presence of 5 and 50 nM dexamethasone (Dexa; 
D-4902; Sigma-Aldrich) and/or 5 µM -secretase inhibitor (N-[N-(3,5-
difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester [DAPT]; EMD) 
or with the DMSO/vehicle alone. Cell cycle activation was quantified using 
KI67 labeling, and apoptosis was measured by annexin  V–FITC staining (BD) 
on harvested leukemic cells and analyzed by FACS.
Online supplemental material. Fig. S1 shows examples of identical ge-
nomic lesions in diagnosis and xenograft leukemia samples. Fig. S2 shows that 
diagnosis and xenograft leukemias can derive from a common prediagnosis 
ancestor clone and also shows specific backtracking data in diagnosis samples 
of genomic abnormalities identified in xenograft samples. Fig. S3 shows that 
xenografted leukemias have increased leukemia-initiating activity relative to 
diagnosis leukemias. Fig. S4 shows a model for clonal selection and gain of ma-
lignancy in patient and xenograft. Table S1 lists the enriched Gene Ontology 
terms in the overexpressed in T-ALL xenografts gene set. Table S2, included as 
an Excel file, is the list of copy number aberrations in T-ALL samples. Table S3, 
included as an Excel file, is the list of NOTCH1, FBXW7, PTEN, and WT1 
mutations in T-ALL samples. The overexpressed in T-ALL xenografts gene set is 
also listed in the supplemental material. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20110105/DC1.
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Fluorescent  in  situ  hybridization  (FISH)  analysis. The unbalanced 
translocation TCRB-MYC suspected on the array CGH profile in the xeno-
graft sample of case XLE_22 was confirmed by FISH analysis using the bac-
terial artificial chromosome probes RP11-460A11 (green; at the centromeric 
part of the MYC locus on 8q24) and RP11-78G15 (red; at the telomeric 
part of the TCRB locus on 7q34) by demonstrating a fusion in the xenograft 
but not diagnosis nuclei. Probes were obtained from AmpliTech.
NOTCH1, FBXW7, PTEN, and WT1 mutations screening. Mutational 
screening of the NOTCH1, FBXW7, and WT1 genes was performed. 
NOTCH1 mutations were searched for in the N- and C-terminal regions of 
the heterodimerization domain (exons 26 and 27, respectively), the transcrip-
tional activation domain, and the PEST domains (distal part of exon 34); extra-
cellular juxtamembrane expansion mutations (exon 28) were also investigated. 
For FBXW7, mutations in the WD40 domain were examined by sequencing 
exons 9 and 10. PTEN mutations were assessed in exon 7, and WT1 muta-
tions were assessed in exon 7.
Quantitative genomic PCR for specific backtracking of abnormalities. 
Lesion-specific quantitative genomic PCR assays were designed based on the 
breakpoint or mutation sequences of four genomic abnormalities identified 
in xenografted T-ALL cells. Genomic deletion breakpoints were mapped by 
tiling primers outward from the genomic locations of CGH array probes de-
fining the minimal regions of deletion at 500-bp intervals to beyond the 
next nondeleted probes telomeric and centromeric to the deletion. A com-
bination of forward and reverse PCR primers was used to amplify the region 
of genomic deletion, and the genomic deletion breakpoints were determined 
by direct sequencing of PCR products. A specific real-time PCR assay using 
TaqMan probes or SYBR Green reagents (Applied Biosystems) was designed 
for each lesion analyzed. Quantification of the genomic lesion in diagnosis 
sample cells was performed using 10-fold dilutions of the xenograft DNA 
harboring the lesion. Experiments and interpretation of results were per-
formed according to guidelines for minimal residual disease assessment.
Large-scale gene expression analyses. 9 pairs of xenograft and diagnosis 
T-ALL samples along with a series of 93 T-ALL samples (73 primary T-ALL 
and 20 T cell lines) were profiled using large-scale gene expression analysis on the 
GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix). RNA extrac-
tion, labeling, and microarray hybridization were processed in the same manner 
for all samples in the same set of experiments. Microarray data files are avail-
able from ArrayExpress under accession no. E-MTAB-604. After robust mul-
tichip average normalization, unsupervised hierarchical clustering was performed 
using Dchip tools as previously reported on another set of T-ALLs (Soulier et al., 
2005). Probe sets for the unsupervised clustering shown in Fig. 4 A were se-
lected on expression variability and reliability among samples after robust 
multichip average normalization on the following criteria: SD > 1.5 and gene 
expression >6 in at least 10% of cases and nonredundant genes, resulting in 
880 probe sets. To avoid spurious clustering caused by contaminating BM cells, 
probe sets with high expression in normal BM samples were identified using 
unsupervised hierarchical classification and excluded, as well as genes from 
chromosome Y, resulting in a final list of 749 probe sets. The Cell cycle and 
Mitosis cluster identified from this analysis largely overlaps with the Cluster 6 
previously defined (Soulier et al., 2005). Comparison between the paired   
xenografts and diagnosis samples was performed using the SAM procedure 
(target proportion of false discoveries, 0.005; 500 permutations; percentile for 
determining falsely called genes, 90), resulting in 100 probe sets “overexpressed 
T-ALL xenograft” (58 unique genes; see list in supplemental material). Bio-
logical pathways which were statistically linked with this gene set were tested 
using Gene Ontology and the Broad institute tools. Gene set enrichment 
analysis of this gene set in relapse versus diagnosis leukemias was performed 
using two series of paired ALL. These series include n = 35 ALL pairs (32 B cell 
progenitor ALLs and 3 T-ALLs; Bhojwani et al., 2006) and n = 41 pairs (27 B cell 
progenitor ALLs and 14 T-ALLs; Staal et al., 2010). Means of probe set ex-
pression were ranked using paired Student’s t tests, and 1,000 permutations 
were performed to calculate nominal probabilities as indicated.JEM VOL. 208, April 11, 2011  661
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